Donor ACE gene polymorphism: A genetic risk factor for accelerated coronary sclerosis following cardiac transplantation

European Heart Journal

Volumn 19, Issue 2, 1998, Pages 319-325

  Cunningham, D A ^a   Crisp, S J ^a   Barbir, M ^a   Lazem, F ^a   Dunn, M J ^a   Yacoub, M H ^a  

^a Heart Science Centre ^*

Author keywords

Angiotensin; Arteriosclerosis; Genes; Transplantation

Indexed keywords

CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE;

ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DONOR; FAMILY HISTORY; FEMALE; GENDER; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR;

ACUTE DISEASE; ALLELES; CORONARY ARTERIOSCLEROSIS; FEMALE; GENOTYPE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SEX CHARACTERISTICS; TISSUE DONORS;

EID: 0031881382     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0587     Document Type: Article

References (49)

1. Uretsky BF, Murali S, Reddy PS et al. Development coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827-34.
2. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339: 1566-70.
3. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant 1992; 11: S124-32.
4. Barbir M, Kushwaha S, Hunt B et al. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 1992; 340: 1500-2.
5. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. Maintenance of blood pressure by the reninangiotensin system in normal man. Nature 1981; 291: 329-31.
6. Paul M, Bachmann J, Ganten D. The tissue renin angiotensin systems in cardiovascular disease. Trends in Cardiovasc Med 1992; 2: 94-9.
7. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475-82.
8. Powell JS, Clozel JP, Muller RK et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8.
9. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
10. The SOLVD Investigators. Effect of captopril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
11. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens 1991; 9: 3-15.
12. Cambien F, Poirer O, Lecerf L et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
13. Ludwig E, Corneli PS, Anderson JL, Marshall HW, Lalouel JM, Ward RH. Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 1995; 91: 2120-4.
14. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ, Caulfield M. A DNA variant at the angiotensin-converting enzyme locus associates with coronary artery disease in the Caerphilly Heart Study. Circulation 1995; 91: 270-4.
15. Hata A, Namikawa C, Sasaki M et al. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest 1994; 93: 1285-7.
16. Tiret L, Bonnardeaux A, Poirer O et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994; 344: 910-3.
17. Bohn M, Bakken A, Erikssen J, Berg K. XbaI polymorphism in DNA at the apolipoprotein B locus is associated with myocardial infarction (MI). Clin Genet 1993; 44: 241-8.
18. Lindpaintner K, Pfeffer MA, Kreutz R et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 332: 706-11.
19. Katsuya T, Koike G, Yee TW et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995; 345: 1600-3.
20. Caulfield M, Lavender P, Farrall M et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330: 1629-33.
21. Jeunemaitre X, Lifton RP, Hunt SC, Williams RR, Lalouel JM. Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1992; 1: 72-5.
22. Herrman BG, Frischauf AM. Isolation of genomic DNA. Methods Enzymol 1987; 152: 180-3.
23. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxy-peptidase 1). Nucleic Acids Res 1992; 20: 1433.
24. Shanmugan V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Applications 1993; 3: 120-1.
25. Fogarty DG, Maxwell AP, Doherty CC, Hughes AE, Nevin NC. ACE gene typing [letter]. Lancet 1994; 343: 851.
26. Gardner MJ, Altman DG. Statistics with confidence - confidence intervals and statistical guidelines. London: BMJ; 1989.
27. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51: 197-205.
28. Barley J, Blackwood A, Carter ND et al. Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. J Hypertens 1994; 12: 955-7.
29. Bonithon Kopp C, Ducimetiere P, Touboul PJ et al. Plasma angiotensin-converting enzyme activity and carotid wall thickening. Circulation 1994; 89: 952-4.
30. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994; 93: 339-46.
31. Rigat B, Hubert C, Alhenc Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
32. Raynolds MV, Bristow MR, Bush EW et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-5.
33. Marian AJ, Yu QT, Workman R, Greve G, Roberts R. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6.
34. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-12.
35. Ohishi M, Fujii K, Minamino T et al. A potent genetic risk factor for restenosis [letter]. Nat Genet 1993; 5: 324-5.
36. Nakai K, Itoh C, Miura Y et al. Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum angiotensin converting enzyme concentration and increased risk for coronary artery disease in the Japanese. Circulation 1994; 90: 2199-202.
37. Castellano M, Muiesan ML, Rizzoni D et al. Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population. The Vobarno Study. Circulation 1995; 91: 2721-4.
38. Hamon M, Bauters C, Amant C et al. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995; 92: 296-9.
39. Samani NJ, Martin DS, Brack M et al. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 1995; 345: 1013-6.
40. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 1992; 11: 9-23.
41. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991; 68: 450-6.
42. Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ Jr, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall [published erratum appears in J Clin Invest 1992 May; 89 (5): 1695]. J Clin Invest 1991; 87: 1300-11.
43. Paul LC, Davidoff A, Benediktsson H. Cardiac allograft atherosclerosis in the rat. The effect of histocompability factors, cyclosporine, and an angiotensin-converting enzyme inhibitor. Transplantation 1994; 57: 1767-72.
44. Gao SZ, Fietze E, Alderman EL et al. Clinical and laboratory correlates of accelerated coronary artery disease in the cardiac transplant patient. Circulation 1987; 76: V56-61.
45. Gao SZ, Schroeder JS, Hunt SA, Valantine HA, Hill IR, Stinson EB. Influence of graft rejection on incidence of accelerated graft coronary artery disease: a new approach to analysis. J Heart Lung Transplant 1993; 12 (6 pt 1): 1029-35.
46. Stovin PG, Sharples L, Hutter JA, Wallwork J, English TA. Some prognostic factors for the development of transplant-related coronary artery disease in human cardiac allografts. J Heart Lung Transplant 1991; 10 (1 Pt 1): 38-44.
47. Hornick P, Smith J, Pomerance A et al. Influence of HLA matching, donor/recipient phenotype and acute rejection episodes. Circulation 1996; 94: I-110.
48. Hruban RH, Beschorner WE, Baumgartner WA, Augustine SM, Reitz BA, Hutchins GM. Accelerated arteriosclerosis in heart transplant recipients: an immunopathology study of 22 transplanted hearts. Transplant Proc 1991; 23 (1 Pt 2): 1230-2.
49. Foegh ML, Khirabadi BS, Nakanishi T, Vargas R, Ramwell PW. Estradiol protects against experimental cardiac transplant atherosclerosis. Transplant Proc 1987; 19 (4 Suppl 5): 90-5.